Amanote Research
Register
Sign In
Costs of Best Supportive Care in the Treatment of Moderate-To-Severe Psoriasis in the United States
Value in Health
- United Kingdom
doi 10.1016/j.jval.2013.08.1158
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2013
Authors
T. Tencer
S. Li
F. Zhang
Publisher
Elsevier BV
Related search
Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States
Dermatology and Therapy
Dermatology
Pharmacy Costs of Specialty Medications for Plaque Psoriasis in the United States
Journal of the American Academy of Dermatology
Dermatology
The Direct Health Care Costs of Obesity in the United States.
American Journal of Public Health
Environmental
Public Health
Occupational Health
Oral Curcumin in the Treatment of Moderate to Severe Psoriasis Vulgaris: A Prospective Clinical Trial
Journal of the American Academy of Dermatology
Dermatology
Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Inpatient Burden of Psoriasis in the United States
Journal of the American Academy of Dermatology
Dermatology
Characterization of Insufficient Responders to Ustekinumab in Patients With Moderate-To-Severe Psoriasis in the US Corrona Psoriasis Registry
Journal of Dermatological Treatment
Dermatology
